Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice

被引：13

作者：

Bonanno, Laura ^{[1
]}

Attili, Ilaria ^{[2
]}

Pavan, Alberto ^{[1
]}

Sepulcri, Matteo ^{[3
]}

Pasello, Giulia ^{[1
,4
]}

Rea, Federico ^{[5
]}

Guarneri, Valentina ^{[1
,4
]}

Conte, PierFranco ^{[1
,4
]}

机构：

[1] IRCCS, Med Oncol 2, Ist Oncol Veneto, Via Gattamelata 64, I-35128 Padua, Italy

[2] IRCSS, Div Thorac Oncol, European Inst Oncol, Milan, Italy

[3] IRCCS, Radiotherapy, Ist Oncol Veneto, Padua, Italy

[4] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[5] Univ Padua, Dept Cardiothorac Surg & Vasc Sci, Thorac Surg, Padua, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2021年 / 163卷

关键词：

Stage III lung cancer; Elderly; Radiotherapy; Chemotherapy; Immunotherapy; Concurrent treatment; Sequential treatment; Comorbidities; COMPREHENSIVE GERIATRIC ASSESSMENT; LOW-DOSE CARBOPLATIN; PHASE-III TRIAL; INDUCTION CHEMOTHERAPY; RADIATION PNEUMONITIS; THORACIC RADIOTHERAPY; PERFORMANCE STATUS; RANDOMIZED-TRIAL; ITALIAN COHORT; OLDER PATIENTS;

D O I：

10.1016/j.critrevonc.2021.103378

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment of locally advanced NSCLC (LA-NSCLC) is focused on multimodal strategy, including chemotherapy and radiotherapy (in combination or as alternative treatments), followed by surgery in selected cases. Recently, durvalumab consolidation after definitive chemo-radiation has shown a meaningful overall survival benefit. However, it is important to note that elderly patients represent a high proportion of NSCLC population and frailty and comorbidities can significantly limit treatment options. Indeed, elderly patients are under-represented in clinical trials and data to drive treatment selection in this category of patients are scanty. Available data, main issues and controversies on multimodal treatment in elderly LA-NSCLC patients will be reviewed in this paper.

引用

页数：10

共 90 条

[1] Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention [J].

Aiello, Anna ;

Farzaneh, Farzin ;

Candore, Giuseppina ;

Caruso, Calogero ;

Davinelli, Sergio ;

Gambino, Caterina Maria ;

Ligotti, Mattia Emanuela ;

Zareian, Nahid ;

Accardi, Giulia .

FRONTIERS IN IMMUNOLOGY, 2019, 10

[2] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].

Albain, Kathy S. ;

Swann, R. Suzanne ;

Rusch, Valerie W. ;

Turrisi, Andrew T., III ;

Shepherd, Frances A. ;

Smith, Colum ;

Chen, Yuhchyau ;

Livingston, Robert B. ;

Feins, Richard H. ;

Gandara, David R. ;

Fry, Willard A. ;

Darling, Gail ;

Johnson, David H. ;

Green, Mark R. ;

Miller, Robert C. ;

Ley, Joanne ;

Sause, Willliam T. ;

Cox, James D. .

LANCET, 2009, 374 (9687) :379-386

[3]

ALBERTI W, 1995, BRIT MED J, V311, P899

[4]

AmericanCancerSociety, 2019, CANC FACTS FIGURES 2

[5] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[6] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[7] Interventions to restore appropriate immune function in the elderly [J].

Aspinall, Richard ;

Lang, Pierre Olivier .

IMMUNITY & AGEING, 2018, 15

[8] Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812) [J].

Atagi, S ;

Kawahara, M ;

Tamura, T ;

Noda, K ;

Watanabe, K ;

Yokoyama, A ;

Sugiura, T ;

Senba, H ;

Ishikura, S ;

Ikeda, H ;

Ishizuka, N ;

Saijo, N .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) :195-201

[9] Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301) [J].

Atagi, Shinji ;

Mizusawa, Junki ;

Ishikura, Satoshi ;

Takahashi, Toshiaki ;

Okamoto, Hiroaki ;

Tanaka, Hiroshi ;

Goto, Koichi ;

Nakagawa, Kazuhiko ;

Harada, Masao ;

Takeda, Yuichiro ;

Nogami, Naoyuki ;

Fujita, Yuka ;

Kasai, Takashi ;

Kishi, Kazuma ;

Sawa, Toshiyuki ;

Takeda, Koji ;

Tomii, Keisuke ;

Satouchi, Miyako ;

Seto, Takashi ;

Ohe, Yuichiro .

CLINICAL LUNG CANCER, 2018, 19 (05) :E619-E627

[10] Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301) [J].

Atagi, Shinji ;

Kawahara, Masaaki ;

Yokoyama, Akira ;

Okamoto, Hiroaki ;

Yamamoto, Nobuyuki ;

Ohe, Yuichiro ;

Sawa, Toshiyuki ;

Ishikura, Satoshi ;

Shibata, Taro ;

Fukuda, Haruhiko ;

Saijo, Nagahiro ;

Tamura, Tomohide .

LANCET ONCOLOGY, 2012, 13 (07) :671-678

← 1 2 3 4 5 6 7 8 9 →